 Home > Biochemistry News > Biotechnology News > Code Announces R&D Agreement with Takeda to Develop Non-Viral Vector Gene Therapies

Code Announces R&D Agreement with Takeda to Develop Non-Viral Vector Gene Therapies

 Last Update: 2022-05-23
 Source: Internet
 Author: User

Tags

moodle platform

liquid design

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Code Biotherapeutics announced today that it has entered into a research and development agreement with Takeda to design and develop gene therapies for rare disease indications using Code Bio’s proprietary 3DNA-targeted non-viral gene drug delivery platform

Code Bio aims to develop genetic medicines to treat and potentially cure serious and life-threatening genetic diseases

According to the official website, the design of the 3DNA platform enables this vector to achieve cell-specific targeting, delivery of large genetic payloads, and the potential for repeated dosing

Image source: Code Bio's official website

Under the agreement, the two companies will utilize Code Bio's 3DNA platform to design and develop a targeted gene therapy for the treatment of rare diseases in the liver, in addition to conducting research in the rare disease program of the central nervous system

References:

[1] Code Biotherapeutics Announces Collaboration with Takeda to Use Proprietary 3DNA Genetic Medicine Delivery Platform to Design and Develop Gene Therapies for Rare Diseases.

(Original abridged)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.